Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.41
-0.38 (-2.97%)
At close: Oct 23, 2026, 4:00 PM EDT
12.50
+0.09 (0.73%)
Pre-market: Oct 26, 2026, 7:58 AM EDT
Generate Biomedicines Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Generate Biomedicines stock has a consensus rating of "Strong Buy" and an average price target of $27. The average 1-year stock price forecast is 117.57% higher than the current stock price, while the lowest is $22 (+77.28%) and the highest is $30 (+141.74%).
Price Target: $27 (+117.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $30 | Buy | Reiterates | $30 | +141.74% | Oct 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $26 | Buy | Reiterates | $26 | +109.51% | Oct 14, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $22 | Buy | Reiterates | $22 | +77.28% | Aug 17, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $30 | Buy | Reiterates | $30 | +141.74% | Jun 25, 2026 |
Financial Forecast
Revenue This Year
29.68M
from 31.89M
Decreased by -6.93%
Revenue Next Year
23.83M
from 29.68M
Decreased by -19.71%
EPS This Year
-2.30
EPS Next Year
-2.28
from -2.30
EPS and Forward PE are based on non-GAAP adjusted numbers.